Regulus Signs Potential $600 Million MicroRNA Collaboration With GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will co-develop microRNA targeted therapeutics in inflammation and immunology.
You may also be interested in...
GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.
GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics
Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.
Regulus Is On The Launch “Platform” With $20M Series A Financing
Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.